Abstract: The invention relates to copolymers comprising: at least one recurrent unit of the following formula (I): at least one recurrent unit of the following formula (II): and at least one recurrent unit of the following formula (III): wherein: R1 and R2 represent, independently of each other, an alkylene group; Z1 is a group of formula —PO3R3R4, R3 and R4 representing, independently of each other, a hydrogen atom, an alkyl group or a cation; Z2 is a group of formula —SO2R5, R5 representing an alkyl group or an aryl group; X and Y represent, independently of each other, a halogen atom or a perfluorocarbon group.

Abstract: According to an embodiment, there is provided an optical transmission element comprising: a fiber including a core made of a first glass and a cladding made of a second glass and covering an outer periphery of the core; and a covering layer covering an outer periphery of the cladding and including a plurality of nonionic surfactant molecules wherein each of the nonionic surfactant molecules is hydrogen-bonded to the cladding.

Abstract: The present invention relates to fatty acid esters of polyols or sulfonated fatty acid esters or sulfonated fatty acid amides containing at least one group Y, where Y stands for CF3—(CH2)a—O—, SF5—, CF3—(CH2)a—S—, CF3CF2S—, [CF3—(CH2)a]2N— or [CF3—(CH2)a]NH—, where a stands for an integer selected from the range from 0 to 5, or formula (I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—, CF3—(CH2)r—S—, CF3CF2—S—, SF5—(CH2)t— or [CF3—(CH2)r]2N—, [CF3—(CH2)r]NH— or (CF3)2N—(CH2)r—, B stands for a single bond, O, NH, NR, CH2, C(O)—O, C(O), S, CH2—O, O—C(O), N—C(O), C(O)—N, O—C(O)—N, N—C(O)—N, O—SO2 or SO2—O, R stands for alkyl having 1 to 4 C atoms, b stands for 0 or 1 and c stands for 0 or 1, q stands for 0 or 1, where at least one radical from b and q stands for 1, and r stands for 0, 1, 2, 3, 4 or 5, to processes for the preparation of these compounds, and to uses of these surface-active compounds.

Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

Abstract: The present invention provides a fluorinated surfactant having the general formula: [Rf—(O)t—CQH—CF2—O]n—R—G??(I) wherein Rf represents a partially or fully fluorinated aliphatic group optionally interrupted with one or more oxygen atoms, Q is CF3 or F, R is an aliphatic or aromatic hydrocarbon group, G represents a carboxylic or sulphonic acid or salt thereof, t is 0 or 1 and n is 1, 2 or 3. The surfactant is particularly useful in polymerizing fluorinated monomers in an aqueous emulsion polymerization.

Abstract: Formula (I) compounds: wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together is a saturated heterocyclic ring or amino acid residue; and non-toxic salts and acid addition salts thereof.

Abstract: Formula (I) compounds: wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl subsituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together is a saturated heterocyclic ring or amino acid residue; and non-toxic salts and acid addition salts thereof.

Abstract: Compounds of formula (I); wherein R1 and R2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed.

Abstract: The compound of the formula (I): wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together a saturated heterocyclic ring or amino acid residues; and non-toxic salts thereof and acid addition salts thereof.

Abstract: The present invention relates to a novel class of shaped bodies containing metal-organic frameworks. Said metal-organic frameworks comprise at least one metal ion and at least one at least bidentate organic compound and contain at least one type of micro- and mesopores or micro- or mesopores. Said shaped bodies comprise at least one metal-organic framework material and may optionally contain further substances, in particular at least one supporting material.

Abstract: The present invention relates to a nervonic acid derivatives of formula (I) CH3—(CH2)7—CH═CH—(CH2)13—C(O)—O—(CH2)3—OR  (I) wherein R is hydrogen (H) or a residue of a carboxylic acid; or a salt of the compound where R is H; or a bioprecursor, prodrug thereof. Those compounds wherein R is other than H have pharmacological activity, in particular anti-inflammatory and immunomodulatory effects. Those compounds wherein R is H can be used to prepare the pharmacologically active derivatives.

Abstract: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): 1

Abstract: Perfluorinated esters of alkanoyl-L-carnitine of the formula (I): are useful as cationic lipids for the intracellular delivery of pharmacologically active compounds.

Abstract: Sulfur heteroatom substitution at the C4 position of 18F-labeled fatty acids yields a tracer that is retained in proportion to the beta-oxidation rates in mammalian tissue, particularly hypoxic myocardium. Most preferably, the invention is embodied in an [18F]fluoro-4-thia-fatty acid having a chain length of between 8 to 20 carbon atoms. The 18F-labeled 4-thia fatty acids of this invention find particular utility the radiolabelling of tissue sites (e.g., myocardium) for purposes of positron emission tomography.

Abstract: The compound 7,10,12-trihydroxy-8(E)-octadecenoic acid (TOD) has been produced by bioconversion of ricinoleic acid by Pseudomonas aeruginosa PR3. TOD and derivatives thereof are useful for controlling biological organisms, such as fungi and insects.

Abstract: Formula (I) compounds: wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl subsituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together is a saturated heterocyclic ring or amino acid residue; and non-toxic salts and acid addition salts thereof.

Abstract: A method of preparing an ester of a carboxylic acid functionalized with a moiety selected from the group consisting of halides, sulfonates, ethers, hydroxyl, amines, and aldehydes, said method comprising: (a) providing either a carboxylic acid having a vinyl group or an ester thereof; (b) functionalizing the vinyl carbon closest to the carboxyl group with said moiety, wherein said functionalizing comprises cleaving said vinyl group.

Abstract: Fluorine containing oxyvinyl compounds characterized by having one or more oxyvinyl groups separated from fluorine containing groups by at least one alkylene group having 2-8 carbon atoms and by at least one oxygen atom in addition to the oxygen on the oxyvinyl. In general the compounds of the invention have the generic formula:Rz(L).sub.a (Ry).sub.b OROCH.dbd.CH.sub.2.Where L is .dbd.CHCOOROCH.dbd.CH.sub.2 ; a is number of 0 to about 1; R.sub.y is --CO--; b is a number of 0 to about 1; R is cycloalkane or (CH.sub.2).sub.x --, where x is a number of about 2 through about 10; R.sub.z is R.sub.f C.sub.n H.sub.m where R.sub.f is a fluorinated alkylene moiety of about 1 to about 12 carbon atoms which may be linear or branch chained and may contain a further --OROCH.dbd.CH.sub.2 group; n is an integer of about 1 through about 6; and m is an integer of n to 2n.

Abstract: Iodinated fatty acid esters, iodinated fatty acids and fluid pharmaceutical-grade stable derivatives thereof are produced by iodohydrination in an organic medium using alkylsilylated derivatives, such as trimethylsilyl chloride or trimethylchlorosilane, that react with an alkaline iodide such as sodium iodide, whereafter hydroiodic acid is formed in situ by exposure to water and the hydroiodic acid is reacted with fatty acid esters and particularly rapeseed oil fatty acid methyl esters that may be used as a biofuel for gasoline engines to provide a low-cost product, and are used therapeutically, in particular for treating goitre linked to iodine deficiency.

Abstract: A process for producing an omega-functionalized aliphatic carboxylic acid starting from cyclohexanone and omega-functionalized .alpha.-olefins or acrylic esters. The process comprises an addition step, an oxidation step, an isomerization step, and one or more hydrogenation steps. The process allows to use raw materials that are available at low cost and to achieve high selectivity and high yield with industrially simple steps. The process includes the production of new intermediate products, including 2-oxepanone-7-substituted products.

Abstract: A novel compound, 12,13,17-trihydroxy-9(Z)-octadecenoic acid (THOA) was produced from linoleic acid by microbial transformation at 25% yield. The newly isolated microbial strain catalyzing this transformation was identified as Clavibacter sp. ALA2 (Accession No. NRRL B-21660). THOA and its derivatives have application as antifungal agents.

Abstract: Methods for stereospecific synthesis of 9-cis olefins and retinoids. In one particular aspect, a cis olefin is generated via a lactol ring opening with complete retention of double bond configuration.

Abstract: The invention relates to compounds of formula (I): ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently selected from: (i) saturated or unsaturated fatty acyl groups, preferably having from 14 to 24 carbon atoms, more preferably of a type found in nature; or(ii) groups of formula (II): ##STR2## wherein R.sup.4 and R.sup.5 are independently selected from hydrogen atoms, C.sub.1-4 alkyl groups and aryl groups, preferably C.sub.6-10 aryl groups; n represents the integers 0 or 1; A represents either a chemical bond or a straight or branched C.sub.1-6 alkylene chain and R.sup.6 is a triiodinated phenyl group which may also carry other substituents. The invention also relates to X-ray contrast media containing these compounds, as well as methods of enhancing X-ray images of a human subject wherein the contrast media are administered to the subject prior to imaging.

Abstract: Aromatic acid-derived lipophilic polyhalogenated compounds are provided for use as contrast agents in diagnostic imaging or as therapeutic agents. These compounds are particularly useful when incorporated into an oil-in-water emulsion for tissue-specific delivery to the liver. For hepatocyte-selective delivery, the emulsion is chylomicron remnant-like by being in a size range of 50 to 200 nm and having a composition simulating naturally-occuring chylomicron remnants.

Abstract: This invention relates to novel processes for synthesizing intermediates in the preparation of N-aryl and N-heteroarylamide inhibitors of the enzyme acyl coenzyme A: cholesterol acyltransferase (ACAT), and to novel intermediates used in such processes.

Abstract: Compounds of the formula ##STR1## in which A is oxygen, sulfur or --NR.sub.1 --;B is C.sub.2 -C.sub.6 alkylene,D-E is --O--E, --S--E, --O--CH.sub.2 --E, --O--C(.dbd.O)--E, --O--C(.dbd.O)--O--E, --O--C(.dbd.O)--N(H)--E or --O--C(.dbd.S)--N(H)--E;E is phenyl; phenyl which is substituted by one to three substituents; a five-membered aromatic heterocycle having one to three hetero atoms; a five-membered aromatic heterocycle which has one to three hetero atoms and which is substituted by one or two substituents; a six-membered aromatic heterocycle which has one to three nitrogen atoms; or a six-membered aromatic heterocycle which has one to three nitrogen atoms and which is substituted by one or two substituents;L is halogen or methyl;X is fluorine;Y is chlorine or fluorine;Z is hydrogen, fluorine or methyl;m is the number zero, one, two, three, four or five;n is the number zero, one or two andR.sub.1 is hydrogen, C.sub.1 -C.sub.

Abstract: This specification provides a polymeric material useful for manufacturing contact lenses having improved oxygen permeability. The contact lenses prepared from the polymeric material of the invention show improved hydrophilicity and enhanced oxygen permeability as compared with that made of the conventional fluoroalkyl-containing polymeric materials.